End-of-day quote
Nasdaq
03:30:00 15/05/2024 am IST
|
5-day change
|
1st Jan Change
|
27.69
USD
|
-0.89%
|
|
+14.00%
|
+166.25%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
154.1
|
752.2
|
-
|
-
|
Enterprise Value (EV)
1 |
154.1
|
438.7
|
233.7
|
752.2
|
P/E ratio
|
-1.23
x
|
-11.7
x
|
-9.85
x
|
-7.88
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
54.5
x
|
412
x
|
380
x
|
278
x
|
EV / Revenue
|
54.5
x
|
241
x
|
118
x
|
278
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-5.62
x
|
-2.73
x
|
-7.66
x
|
FCF Yield
|
-
|
-17.8%
|
-36.7%
|
-13.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
14,818
|
29,349
|
-
|
-
|
Reference price
2 |
10.40
|
25.63
|
25.63
|
25.63
|
Announcement Date
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
2.826
|
1.824
|
1.977
|
2.707
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-48.17
|
-77.53
|
-97.8
|
-130
|
Operating Margin
|
-
|
-1,704.67%
|
-4,251.55%
|
-4,945.61%
|
-4,802.42%
|
Earnings before Tax (EBT)
1 |
-
|
-43.56
|
-63.65
|
-88.36
|
-120.8
|
Net income
1 |
-28.48
|
-43.56
|
-63.65
|
-88.36
|
-120.8
|
Net margin
|
-
|
-1,541.22%
|
-3,490.48%
|
-4,468.65%
|
-4,462.44%
|
EPS
2 |
-7.100
|
-8.450
|
-2.193
|
-2.601
|
-3.252
|
Free Cash Flow
1 |
-
|
-
|
-78
|
-85.74
|
-98.21
|
FCF margin
|
-
|
-
|
-4,277.09%
|
-4,335.68%
|
-3,627.88%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/08/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.924
|
0.457
|
0.874
|
0.3137
|
0.3137
|
0.3137
|
0.319
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.76
|
-12.96
|
-17.84
|
-18.56
|
-19.88
|
-21.26
|
-18.91
|
Operating Margin
|
-1,705.52%
|
-2,835.01%
|
-2,041.65%
|
-5,917.74%
|
-6,338.14%
|
-6,778.46%
|
-5,927.43%
|
Earnings before Tax (EBT)
1 |
-14.76
|
-10.56
|
-13.75
|
-14.95
|
-16.33
|
-18.64
|
-15.63
|
Net income
1 |
-14.76
|
-10.56
|
-13.75
|
-14.95
|
-16.33
|
-18.64
|
-15.63
|
Net margin
|
-1,597.73%
|
-2,311.38%
|
-1,573%
|
-4,766.47%
|
-5,206.43%
|
-5,942.76%
|
-4,898.43%
|
EPS
2 |
-3.780
|
-
|
-0.5400
|
-0.5317
|
-0.5767
|
-0.6317
|
-0.5500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/23
|
21/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
314
|
519
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-78
|
-85.7
|
-98.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0.13
|
0.18
|
0.21
|
Capex / Sales
|
-
|
-
|
7.02%
|
9.31%
|
7.7%
|
Announcement Date
|
01/08/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
25.63
USD Average target price
49.29
USD Spread / Average Target +92.30% Consensus |
1st Jan change
|
Capi.
|
---|
| +166.25% | 752M | | +9.42% | 115B | | +11.84% | 106B | | -1.05% | 21.96B | | -14.15% | 21.87B | | -5.29% | 19.21B | | -4.16% | 18.08B | | -38.29% | 17.71B | | +7.99% | 14.32B | | +36.24% | 12.42B |
Bio Therapeutic Drugs
|